The IPO Buzz: Acrivon Therapeutics (ACRV) Launches $100.3 Million IPO
Acrivon Therapeutics (ACRV proposed), a cancer biotech, filed terms – 5.9 million shares at $16.00 to $18.00 – early today (Thursday, Nov. 3, 2022) and landed on next week’s IPO Calendar. The deal, which will raise $100.3 million if priced at the $17.00 mid-point, launched today as well. It’s set to price on Wednesday night, […]
November 3, 2022 Read More